InvestorsHub Logo
Post# of 252191
Next 10
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: urche post# 142225

Sunday, 05/20/2012 3:32:29 AM

Sunday, May 20, 2012 3:32:29 AM

Post# of 252191

This news upsets long held belief of mine that raising HDL, at least natural HDL (as opposed to the abnormal HDL particles associated with CETP inhibitors), is beneficial and a promising investment thesis

While these data suggest that HDL raising alone like what dalcetrapib does, has no impact on MI risk, their note here

Of note, at the cholesterol ester transfer protein (CETP) gene, we did find that common genetic variation reduces risk of myocardial infarction by 4%, a result in line with an earlier meta-analysis. However, the CETP variant both increases HDL cholesterol and lowers LDL cholesterol17 in a manner similar to pharmacological inhibitors of CETP. As such, whether the protection afforded by the CETP variant is due to the change in HDL or LDL cholesterol is difficult to distinguish.

Makes me think other CETP inhibitors that also reduce LDL might work. Of course, if we need them at all is a different question.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.